A new quantitative reverse phase high-performance liquid chromatographic method for the quantification of Rilpivirine hydrochloride in bulk and dosage form

Sonam Patel; Krishnaveni Nagappan; Gouru Santhosh Reddy

doi:10.7324/JAPS.2018.81122

Abstract References Article Metrics Similar Articles Request Permission Related Search Citation Alert By Google Scholar Comment On This Article

Abstract

Objective: The aim of this present study is to develop a precise, accurate, and linear reverse-phase high-performance liquid chromatographic (RP-HPLC) method for the assessment of Rilpivirine hydrochloride in the pharmaceutical dosage form. Methods: The chromatographic system employs a reverse phase shim-pack C18 column (150 × 4.6 mm; 5 μ) using the mobile phase acetonitrile: ammonium acetate buffer (0.05 M) (pH-3.5 equalized with glacial acetic acid) in the proportion of 60:40 v/v, delivered at a flow rate of 0.8 ml/minutes with the detection wavelength of 291 nm. Results: The developed method resulted in retention of Rilpivirine hydrochloride at 4.5 minutes. Rilpivirine hydrochloride exhibited a linear relationship (r2 > 0.999) over the analytical range of 5–50 μg/ml. The precision is represented by a relative standard deviation of 0.709%. The percentage recovery was observed in the range of 98%–102%, indicating the accuracy of the study. The detection limit and quantification limit were found to be 0.104 and 0.315 μg/ml, respectively. Conclusion: A precise, accurate, rapid, and linear RP-HPLC method has been developed and validated for the quantification of Rilpivirine hydrochloride in bulk and in tablet formulation (25 mg) as per ICH Q2A (R2) guidelines. The developed and validated method can further be used for routine analysis of Rilpivirine hydrochloride in various pharmaceutical industries.

Keyword: Rilpivirine hydrochloride RP-HPLC Method optimization Method validation.

Citation:

Patel S, Nagappan K, Reddy GS. A new quantitative reverse phase high-performance liquid chromatographic method for the quantification of Rilpivirine hydrochloride in bulk and dosage forms. J App Pharm Sci, 2018; 8(11): 157–162.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Bakshi M, Shingh S. Development of validated stability indicating assay method—critical review. JPBA, 2002; 78:1011–40. https://doi.org/10.1016/S0731-7085(02)00047-X
Devanaboyina N, Anusha MJ, Bharathi D, Anusha C, Srinu U, Prabhu KNVSS. Liqui chromatography method development and validation for analysis of Rilpivirine in bulk and pharmaceutical dosage form by RP HPLC. IJCNS, 2014; 2(3):104–8.
Fathima N, Reddy PR, Brahmaiah M, Qasimullah, Huq GA. Development and validation of stability indicating RP HPLC methods for determination of impurities in rilpivirine hydrochloride capsules. WJPPS, 2018; 7(1):1118–34.
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use. Validation of analytical procedures: text and methodology ICH Q2 (R1), 2005.
Kavitha KY, Geetha G, Hariprasad R, Venkatnarayana R, Kaviarasu M. Development and valiation of RP UPLC analutiacl method for simultaneous estimation of emtricitabine, Rilpivirine, Tenofovir Disoproxil fumarate and its pharmaceutical dosage form. IRJP, 2013; 4(1): 150–5.
Lieven B, Gerben K, Willy D, Marc F, Alfons W, Esther B. Development of a long-acting injectable formulation with nanoparticles of Rilpivirine (TMC278) for HIV treatment. Eur J Pharma Biopharma, 2009; 72:502–8. https://doi.org/10.1016/j.ejpb.2009.03.006
Madhuri M, Vijaya Sri K, Jain GV. Development and validation of RP HPLC method for Rilpivirine hydrochloride in bulk and use in analysis of prepared nano suspension. Indian Drugs, 2015; 52(04): 42–6.
Marineni B, Krishna V, Sreenivasulu Reddy T. A validated stability indicating HPLC assay method for Rilpivirine hydrochloride in buklk drug. Int J Pharm Bio Sci, 2013; 3(4):278–87.
Reddiah CV, Ramadevi P, Mukkanti K. Effective estimation of Rilpivirine by HPLC method in tablet dosage forms and its invitro dissolution assessment. IJPPS, 2012; 4(2):595–9.
Sarkar M, Sateesh K, Ramesh P. Development and validation RP-HPLC and ultraviolet spectrophotometric methods of analysis for the quantitative estimation of antiretroviral drugs in pharmaceutical dosage form. J Chromatogr B, 2006; 830:349–54. https://doi.org/10.1016/j.jchromb.2005.11.014
Schrijversa R, Desimmiea B, Debysera Z. Rilpivirine: a step forward in tailored HIV treatment. J Lancet, 2011; 378:201–3. https://doi.org/10.1016/S0140-6736(11)60992-6
Sharma M, Saravolatz LD. Rilpivirine: a new nonnucleoside reverse transcriptase inhibitor. J Antimicrob Chemother, 2013; 68:250–6. https://doi.org/10.1093/jac/dks404
Venkatesan S, Kannappan N, Mannemala SS. Stability indicating HPLC method for the simultaneous determination of HIV tablet containing Emtricitabine, Tenofovir Disoproxil Fumarate and Rilpivirine Hydrochloride in pharmaceutical dosage form. Int Sch Rese, 2014; 2014:29: 1-9. https://doi.org/10.1155/2014/849149
UNAIDS. AIDS epidemic update. WHO Regional Office Europe. 2009. WHO Library cataloging

Article Metrics

669 Views 61 Downloads 730 Total

Year

Month

Related Search

By author names

Patel S [PubMed] [Google Scholar ]

Nagappan K [PubMed] [Google Scholar ]

Reddy G S [PubMed] [Google Scholar ]

By article title